News NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
12.64 ^USD	+3.31%		+4.51%	-15.37%

Apr. 24	NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer	CI
Apr. 10	Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024	Apr. 24	BU
NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer	Apr. 24	CI
NovoCure : Corporate responsibility report	Apr. 22	PU
Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	Apr. 10	MT
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research Annual Meeting 2024	Apr. 08	AQ
NovoCure Says New Data Show TTFields' Potential Therapeutic Effects in Pancreatic Cancer	Apr. 05	MT
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024	Apr. 05	BU
Wells Fargo Cuts Price Target on NovoCure to $42 From $49, Keeps Overweight Rating	Apr. 03	MT
Novocure to Report First Quarter 2024 Financial Results	Apr. 01	BU
Novocure - METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer	Mar. 28	AQ
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases	Mar. 28	AQ
Zai Lab, Novocure Say TTFields Therapy Delays Intracranial Progression in Non-Small Cell Lung Cancer Brain Metastases Patients	Mar. 27	MT
Sector Update: Health Care Stocks Edge Higher Pre-Bell Wednesday	Mar. 27	MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	Mar. 27	MT
Sector Update: Health Care	Mar. 27	MT
NovoCure Says Trial of Therapy for Brain Metastases From Lung Cancer Met Primary Endpoint; Shares Jump Pre-Bell	Mar. 27	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Board Governor Waller's Speech	Mar. 27	MT
Transcript : NovoCure Limited - Special Call	Mar. 27
Novocure's lung cancer therapy succeeds in late-stage trial	Mar. 27	RE
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer	Mar. 27	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Summary

Filters